The SIRIUS trial assessed the safety and effectiveness of the sirolimus-eluting Bx VELOCITY stent compared to an uncoated stent in reducing target vessel failure. The trial involved over 1100 patients with de novo coronary lesions treated with either the sirolimus-eluting stent or uncoated stent. At 9 months, the primary endpoint of target vessel failure occurred in significantly fewer patients in the sirolimus-eluting stent group compared to the uncoated stent group. Secondary endpoints including MACE and TLR were also significantly reduced with the sirolimus-eluting stent at 12 months.

3. SIRIUS Study design

6. SIRIUS: Study Design De Novo Coronary Lesions Diameter: 2.5-3.5 mm Length: 15-30 mm Control Bx VELOCITY TM n = 556 CYPHER TM n = 545 n = 1101 patients Angiographic Sub-study: first 850 pts (FU at 8 months) IVUS Substudy: 250 pts at selected sites (FU at 8 months)

10. SIRIUS: Study Procedure n = 1100 pts Single de novo native coronary lesion Pre-dilation (balloons only) Post-dilation (high pressure balloons) Bx – Sirolimus vs. non-coated

11. SIRIUS: Study Flow All Randomised Patients n = 1101 CYPHER n = 533 Control Bx VELOCITY TM n = 525 Angio FU at 8 Months = 85.4% Clinical FU at 9 Months = 95.7% Angio FU at 8 Months = 84.7% Clinical FU at 9 Months = 95.8% De-registered CYPHER (n=23) De-registered Control Bx VELOCITY TM (n=20)

12. SIRIUS: Patient Demographics 32.9 28.2 Prior MI 23.1 26.3 Prior PCI 22.4 17.7 Current Smoker 67.8 67.6 Hypertension 74.6 72.6 Hyperlipidaemia 28.2 24.6 Diabetes Mellitus 62.4 62.1 Mean age (years) 69.7 72.6 Male Control (%) (n=525) CYPHER (%) (n=533)

13. SIRIUS: Baseline Lesion Characteristics 32.4 30.0 RCA 0.6 0.6 Other 20.6 26.0 C 33.5 32.6 B2 38.1 34.0 B1 7.8 7.4 AHA/ACC A 23.9 25.3 LCx 43.2 44.2 LAD Control (%) (n=525) CYPHER (%) (n=533)

14. SIRIUS: Baseline Lesion Characteristics (2) 13.7 15.4 3 14.4 ± 5.8 14.4 ± 5.7 Mean Lesion length 13.4 15.2 >20mm 66.2 64.8 10-20mm 20.4 20.0 Lesion length <10mm 28.8 25.3 2 57.5 59.3 No. of diseased coronaries 1 Control (%) (n=525) CYPHER (%) (n=533)

15. SIRIUS: Stents Implanted 26.9 28.5 Patients with overlapping stents 1.4 ± 0.6 1.4 ± 0.7 Mean stents per patient (n) 21.2 ± 6.8 21.5 ± 6.7 Stent length (mm) 0.8 1.5  4 4.6 4.9 3 29.5 28.6 2 37.0 35.1 3.5 64.9 65.0 Number of stents per patient 1 45.8 45.6 3.0 17.2 19.3 Diameter 2.5 Control (%) CYPHER (%)

16. SIRIUS: Other Procedural 59.2 60.4 IIbIIIa during procedures (%) 1.2 ± 0.6 1.2 ± 0.9 Mean hospital stay (days) Control CYPHER

19. SIRIUS: QCA Late Loss Analysis (9-month) Margins = 5mm either side of stent P < 0.001 P < 0.001 P < 0.001

20. SIRIUS 12 -month Results

21. SIRIUS: Clinical events (all events to 360 days) Events 24.8 (130) 22.3 (117) 6.7 (35) 1.3 (7) 5.5 (29) 19.2 (101) 3.0 (16) 20.0 (105) 1.7 (9) 3.4 (18) 0.8 (4) Control % n = 525 0.449 <0.001 0.295 2.3 (12) 4.9 (26) 0.9 (5) Non Q-wave TLR TLR-CABG <0.001 4.3 (23) TLR-PCI <0.001 9.8 (52) TVF <0.001 8.3 (44) MACE <0.001 3.6 (19) 0.6 (3) 3.2 (17) TVR (non TLR) TVR-CABG TVR-PCI 0.723 3.0 (16) MI (all) 0.547 1.3 (7) Death P-value CYPHER % n = 533

22. SIRIUS: Clinical events (diabetics only to 360 days) Note that TLR & TVR rates are clinically driven only and do not include angiographically driven procedures Events 29.1 (43) 8.1 (12) 0.0 (0) 8.1 (12) 25.0 (37) 4.1 (6) 26.4 (39) 2.0 (3) 4.1 (6) 0.7 (1) Control % n = 148 1.5 (2) 8.4 (11) 0.8 (1) Non Q-wave TLR TLR-CABG 8.4 (11) TLR-PCI 11.5 (15) MACE 5.3 (7) 0.0 (0) 5.3 (7) TVR (non TLR) TVR-CABG TVR-PCI 2.3 (3) MI (all) 1.5 (2) Death CYPHER % n = 131

23. Reduction in TLR by Patient Characteristics Lesion Length Reference Vessel Diameter 72.8 74.8 76.5 75.3 76.6 77.6 12mm - 15mm 75.7 77.0 2.5mm < RVD < 3.0mm 74.1 75.9 RVD < 2.5mm 70.8 73.8 RVD < 2.5mm 73.4 75.5 2.5mm < RVD < 3.0mm 75.6 76.9 RVD > 3.0mm Diabetics 77.0 77.8 RVD > 3.0mm Non-Diabetics > 15mm < 12mm

24. CP1104360-1 Freedom from events (%) Post procedure (days) Cypher TLR Control TLR Cypher MACE Control MACE Cypher TVF Control TVF Event-free survival at 1 year for TLR, MACE & TVF

25. SIRIUS: TLR Events Overall 4. 9 20.0 0.0001 1 5 2 M ale 5.2 20.5 0.0001 1 53 Female 4 .1 1 9.0 0.000 2 1 49 Diabetes 8 . 4 2 6.4 0.000 2 1 80 No Diabetes 3. 7 1 7.6 0.0001 1 38 LAD 6 . 0 23.0 0.0001 17 0 Non-LAD 4 .1 18.0 0.0001 1 4 0 Small Vessel (<2.75) 6. 6 22 . 3 0.0001 15 7 Large Vessel 3.1 18.2 0.0001 1 51 Short Lesion 4.0 1 8.6 0.0001 1 46 Long Lesion (>13.5) 6.0 2 1 .9 0.0001 1 58 Overlap 5 .7 23 . 2 0.000 1 1 75 No Overlap 4.5 1 8.6 0.0001 1 4 1 Hazards Ratio 95% CI 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0 0.7 0.8 0.9 CYPHER Control P-value CYPHER better # events prevented per 1,000 patients

26. SIRIUS: Stent Thrombosis * 234 days post-procedure ** 40, 150 and 181 days post-procedure 0 0 Acute (  24 hours) 0.8 (4) 0.6 (3)** 0.2 (1) Control n=525 % (n) 0.4 (2) Total 0.2 (1)* Late (31- 36 0 days) 0.2 (1) Sub-acute (1-30 days) CYPHER n=533 % (n)